WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H556350
CAS#: Unknown
Description: HYNIC-PSMA is a PSMA based ligand, which can bind radio-active metal ion and used as a tumor-imaging agent in prostate cancer. 99mTc-HYNIC-PSMA is a novel technetium-99m-labeled small-molecule inhibitor of prostate-specific membrane antigen (PSMA) for detection of prostate cancer. 99mTc-HYNIC-PSMA showed high tracer uptake (with a tumor-to-background ratio of 9.42 ± 2.62) in the malignant lesions of PCa patients, making it a promising radiopharmaceutical imaging method for site-specific management of PCa.
Hodoodo Cat#: H556350
Name: HYNIC-PSMA
CAS#: Unknown
Chemical Formula: C25H38N6O9
Exact Mass: 566.27
Molecular Weight: 566.612
Elemental Analysis: C, 52.99; H, 6.76; N, 14.83; O, 25.41
Synonym: HYNIC-PSMA;
IUPAC/Chemical Name: (2S)-2-[[(1S)-1-carboxy-5-[6-[(4-hydrazinylbenzoyl)amino]hexanoylamino]pentyl]carbamoylamino]pentanedioic acid
InChi Key: QYMJSGVMFQYTOI-OALUTQOASA-N
InChi Code: InChI=1S/C25H38N6O9/c26-31-17-10-8-16(9-11-17)22(35)28-15-4-1-2-7-20(32)27-14-5-3-6-18(23(36)37)29-25(40)30-19(24(38)39)12-13-21(33)34/h8-11,18-19,31H,1-7,12-15,26H2,(H,27,32)(H,28,35)(H,33,34)(H,36,37)(H,38,39)(H2,29,30,40)/t18-,19-/m0/s1
SMILES Code: O=C(O)[C@@H](NC(N[C@H](C(O)=O)CCCCNC(CCCCCNC(C1=CC=C(NN)C=C1)=O)=O)=O)CCC(O)=O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 566.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Ghaedian T, Abdinejad M, Nasrollahi H, Ghaedian M, Firuzyar T. Comparing the role of 99mTc-HYNIC-PSMA-11 and 99mTc-MDP scintigraphy for the initial staging of intermediate to high-risk prostate cancer. Nucl Med Commun. 2023 Jul 18. doi: 10.1097/MNM.0000000000001733. Epub ahead of print. PMID: 37464793.
2: Wang T, Zhao L, Qiao W, Sun N, Zhao J, Xing Y. The efficacy of 99mTc-HYNIC-PSMA SPECT/CT in detecting primary lesions and metastasis in newly diagnosed prostate cancer. Front Oncol. 2023 Jun 2;13:1165694. doi: 10.3389/fonc.2023.1165694. PMID: 37333816; PMCID: PMC10272716.
3: Li B, Duan L, Shi J, Han Y, Wei W, Cheng X, Cao Y, Kader A, Ding D, Wu X, Gao Y. Diagnostic performance of 99mTc-HYNIC-PSMA SPECT/CT for biochemically recurrent prostate cancer after radical prostatectomy. Front Oncol. 2022 Dec 7;12:1072437. doi: 10.3389/fonc.2022.1072437. PMID: 36568205; PMCID: PMC9768541.
4: Yang H, Gao Z, Xu X, Liu C, Hu S, Zhang J, Song S. Dosimetry estimation and preliminary clinical application of [99mTc]Tc-HYNIC-PSMA-XL-2 in prostate cancer. Ann Nucl Med. 2023 Jan;37(1):60-69. doi: 10.1007/s12149-022-01804-x. Epub 2022 Nov 8. PMID: 36346503.
5: Orunmuyi AT, Oladeji AA, Azodoh EU, Omisanjo OA, Olapade-Olaopa EO. Planar 99m Tc-PSMA Imaging of Prostate Cancer in a Low-Resource Setting: A Series Report. World J Nucl Med. 2022 Jun 28;21(2):142-147. doi: 10.1055/s-0042-1750336. PMID: 35865161; PMCID: PMC9296248.
6: Zhang J, Zhang J, Xu X, Lu L, Hu S, Liu C, Cheng J, Song S, Zhang Y, Shi LQ. Author Correction: Evaluation of Radiation dosimetry of 99mTc-HYNIC- PSMA and imaging in prostate cancer. Sci Rep. 2020 Oct 23;10(1):18494. doi: 10.1038/s41598-020-74851-x. Erratum for: Sci Rep. 2020 Mar 6;10(1):4179. PMID: 33097773; PMCID: PMC7584582.
7: Zhang J, Zhang J, Xu X, Lu L, Hu S, Liu C, Cheng J, Song S, Zhang Y, Shi LQ. Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer. Sci Rep. 2020 Mar 6;10(1):4179. doi: 10.1038/s41598-020-61129-5. Erratum in: Sci Rep. 2020 Oct 23;10(1):18494. PMID: 32144340; PMCID: PMC7060171.
8: García-Pérez FO, Davanzo J, López-Buenrostro S, Santos-Cuevas C, Ferro-Flores G, Jímenez-Ríos MA, Scavuzzo A, Santana-Ríos Z, Medina-Ornelas S. Head to head comparison performance of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients. Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):332-340. PMID: 30510850; PMCID: PMC6261875.
9: Liu C, Zhu Y, Su H, Xu X, Zhang Y, Ye D, Hu S. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy. Prostate. 2018 Dec;78(16):1215-1221. doi: 10.1002/pros.23696. Epub 2018 Jul 19. PMID: 30027591.
10: Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT. Prostate. 2017 Aug;77(11):1205-1212. doi: 10.1002/pros.23379. Epub 2017 Jun 26. PMID: 28649735.
11: Ferro-Flores G, Luna-Gutiérrez M, Ocampo-García B, Santos-Cuevas C, Azorín- Vega E, Jiménez-Mancilla N, Orocio-Rodríguez E, Davanzo J, García-Pérez FO. Clinical translation of a PSMA inhibitor for 99mTc-based SPECT. Nucl Med Biol. 2017 May;48:36-44. doi: 10.1016/j.nucmedbio.2017.01.012. Epub 2017 Feb 3. PMID: 28193503.
